Engineered immune cells take aim at blood cancers

NCT ID NCT00586391

Ongoing Disease control Sponsor: Baylor College of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new treatment for people with certain B-cell blood cancers (lymphoma, ALL, or CLL) that have returned or not responded to standard therapy. The treatment uses the patient's own T cells, which are modified in the lab to recognize and attack cancer cells carrying a marker called CD19. The main goals are to find a safe dose and to see how long the modified cells survive in the body.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia B-cell chronic lymphocytic leukemia B-cell neoplasm B-cell non-Hodgkin lymphoma neoplasm Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOCYTIC LEUKEMIA B CELL LYMPHOMA CHRONIC LYMPHOCYTIC LEUKEMIA

Contacts and locations

Locations

Houston Methodist Hospital

Houston, Texas, 77030, United States
Texas Children's Hospital

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.